Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
Elevai Labs Inc. (NASDAQ: ELAB) announces the launch of S-Series Root Renewal System, marking its entry into the hair care market through subsidiary Elevai Skincare. The three-part system includes shampoo, conditioner, and serum, featuring proprietary PREx Exosomes™ and Y100™ technologies targeting scalp and hair health at the cellular level.
The system will initially launch through select medical aesthetics partners before a full e-commerce rollout in January 2025. The product combines nano-encapsulated growth factors and AI-discovered molecules supporting mitochondrial function. This marks Elevai Skincare's first new product launch since 2022, with BosleyMD® recognizing Y100 technology as a major innovation in hair loss treatment.
Elevai Labs Inc. (NASDAQ: ELAB) annuncia il lancio del S-Series Root Renewal System, segnando il suo ingresso nel mercato della cura dei capelli attraverso la controllata Elevai Skincare. Il sistema in tre parti comprende shampoo, balsamo e siero, con tecnologie proprietarie PREx Exosomes™ e Y100™ che mirano a migliorare la salute del cuoio capelluto e dei capelli a livello cellulare.
Il sistema sarà inizialmente lanciato attraverso partner selezionati di estetica medica prima di un lancio completo e-commerce nel gennaio 2025. Il prodotto combina fattori di crescita nano-encapsulati e molecole scoperte dall'IA che supportano la funzione mitocondriale. Questo rappresenta il primo lancio di un nuovo prodotto da parte di Elevai Skincare dal 2022, con BosleyMD® che riconosce la tecnologia Y100 come una grande innovazione nel trattamento della perdita di capelli.
Elevai Labs Inc. (NASDAQ: ELAB) anuncia el lanzamiento del S-Series Root Renewal System, marcando su entrada en el mercado del cuidado capilar a través de su filial Elevai Skincare. El sistema de tres partes incluye champú, acondicionador y suero, y presenta las tecnologías patentadas PREx Exosomes™ y Y100™ que se dirigen a la salud del cuero cabelludo y el cabello a nivel celular.
El sistema se lanzará inicialmente a través de socios seleccionados en estética médica antes de un lanzamiento completo en comercio electrónico en enero de 2025. El producto combina factores de crecimiento nanoencapsulados y moléculas descubiertas por IA que soportan la función mitocondrial. Este es el primer lanzamiento de un nuevo producto por parte de Elevai Skincare desde 2022, con BosleyMD® reconociendo la tecnología Y100 como una gran innovación en el tratamiento de la pérdida de cabello.
Elevai Labs Inc. (NASDAQ: ELAB)은 S-Series Root Renewal System 출시를 발표하며 자회사 Elevai Skincare를 통해 헤어 케어 시장에 진출합니다. 이 3단계 시스템은 샴푸, 컨디셔너 및 세럼으로 구성되어 있으며, 세포 수준에서 두피 및 모발 건강을 목표로 하는 독점 기술인 PREx Exosomes™와 Y100™을 특징으로 합니다.
이 시스템은 선택된 의료 미용 파트너를 통해 처음 출시된 후 2025년 1월에 전체 전자상거래 롤아웃을 진행할 예정입니다. 이 제품은 나노 캡슐화된 성장 인자와 미토콘드리아 기능을 지원하는 AI 발견 분자를 결합합니다. 이는 Elevai Skincare가 2022년 이후 처음으로 출시하는 새로운 제품으로, BosleyMD®는 Y100 기술을 탈모 치료의 주요 혁신으로 인정하고 있습니다.
Elevai Labs Inc. (NASDAQ: ELAB) annonce le lancement du S-Series Root Renewal System, marquant son entrée sur le marché des soins capillaires via sa filiale Elevai Skincare. Le système en trois parties comprend un shampooing, un après-shampooing et un sérum, utilisant des technologies propriétaires PREx Exosomes™ et Y100™ ciblant la santé du cuir chevelu et des cheveux au niveau cellulaire.
Le système sera initialement lancé à travers des partenaires d'esthétique médicale sélectionnés avant un déploiement complet en e-commerce en janvier 2025. Le produit combine des facteurs de croissance nano-encapsulés et des molécules découvertes par l'IA soutenant la fonction mitochondriale. Il s'agit du premier lancement de nouveau produit d'Elevai Skincare depuis 2022, BosleyMD® reconnaissant la technologie Y100 comme une grande innovation dans le traitement de la perte de cheveux.
Elevai Labs Inc. (NASDAQ: ELAB) gibt die Einführung des S-Series Root Renewal System bekannt und markiert damit seinen Eintritt in den Haarpflege-Markt über die Tochtergesellschaft Elevai Skincare. Das dreiteilige System umfasst Shampoo, Conditioner und Serum und enthält die proprietären Technologien PREx Exosomes™ und Y100™, die auf die Gesundheit von Kopfhaut und Haar auf zellulärer Ebene abzielen.
Das System wird zunächst über ausgewählte Partner im Bereich medizinische Ästhetik eingeführt, bevor im Januar 2025 ein vollständiger E-Commerce-Start erfolgt. Das Produkt kombiniert nano-verkapselte Wachstumsfaktoren und von KI entdeckte Moleküle, die die mitochondrialen Funktionen unterstützen. Dies ist die erste Einführung eines neuen Produkts von Elevai Skincare seit 2022, wobei BosleyMD® die Y100-Technologie als bedeutende Innovation in der Behandlung von Haarausfall anerkennt.
- First product launch since 2022, expanding revenue streams
- Strategic entry into high-growth hair care market
- Proprietary technology backed by research and clinical studies
- Planned expansion to e-commerce in January 2025
- product portfolio (only two existing products since 2022)
- Initial distribution through select accounts only
Insights
The hair care market entry with the S-Series Root Renewal System represents a significant strategic expansion for Elevai Labs. The global hair care market, valued at
The dual-technology approach combining PREx Exosomes and Y100 mitochondrial technology creates a unique value proposition in the competitive hair care space. BosleyMD's endorsement of the Y100 technology adds significant credibility. The initial selective distribution through medical aesthetics partners suggests a focus on maintaining premium positioning while building clinical validation before the mass market launch in 2025.
The Root Renewal System's scientific foundation is particularly compelling. The combination of exosome technology with AI-discovered mitochondrial targeting compounds represents a novel approach to hair restoration. Previous research demonstrating effectiveness in reversing hair thinning and reducing scalp inflammation suggests promising clinical potential. The nano-encapsulation of growth factors in a lipid bilayer for follicle support is an innovative delivery mechanism that could enhance efficacy compared to traditional topical treatments.
The partnership with Yuva Biosciences and their AI-discovered Y100 molecule targeting mitochondrial function adds another layer of scientific credibility. This dual-mechanism approach addressing both follicular health and cellular energy production could potentially yield superior results compared to single-mechanism treatments currently available.
- Elevai Skincare Expands into Hair Care with Cutting-Edge Scalp and Hair Health System.
- Root Renewal System Features Exclusive Technologies and Science-Driven Formulations.
- Based on Over 15 Years of Research, 2 Pending Patents, as well as Clinical Studies Supported by Elevai Skincare and by Yuva Biosciences.
NEWPORT BEACH, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- ELEVAI Labs Inc. (Nasdaq: ELAB) (“Elevai” or the “Company”), a diversified holding company, announces the launch of the S-Series Root Renewal System™ (the “Root Renewal System”), a revolutionary entry into the hair care market by its wholly owned subsidiary, Elevai Skincare Inc. (“Elevai Skincare”). The Root Renewal System is a three-part hair and scalp care system consisting of a shampoo, conditioner and serum that combines the latest in patent pending exosome and mitochondrial technology to target scalp and hair health at the cellular level.
This launch reflects Elevai Skincare’s ongoing commitment to science-driven, results-oriented innovations.
The Root Renewal System will be initially introduced through key medical aesthetics partners in select accounts across the United States. This phased rollout strategically positions the product as a premium offering ahead of the full launch, including e-commerce sales, in January 2025. Visit www.ElevaiSkincare.com for more information.
Exclusive Technologies and Groundbreaking Results
The Root Renewal System incorporates two proprietary technologies that, when combined, offer unparalleled results for scalp and hair health:
- Elevai PREx Exosomes™: Nano-encapsulated growth factors protected by a lipid bilayer that support dormant hair follicles and overall scalp health.
- Y100™ by Yuva Biosciences: An AI-discovered small molecule that supports mitochondrial function, which can result in increased cellular energy to rejuvenate hair follicles. BosleyMD® has lauded the Y100 technology as “one of the biggest innovations in hair loss we’ve seen in twenty-five years,” marking its first successful application in their new product line1.
“This system is a testament to our commitment to advancing the science of hair and scalp health,” said Dr. Jordan R. Plews, Chief Executive Officer of Elevai Skincare. “By combining our proprietary PREx Exosomes with Yuva Bio’s Y100 mitochondrial technology, we’ve developed a dual-mechanism solution that promotes follicle rejuvenation and scalp vitality. This groundbreaking synergy is backed by research and designed to deliver transformative results.”
The Root Renewal System builds upon ongoing research conducted by Elevai Skincare in partnership with Carly Klein, President of National Hair Loss Medical Aesthetics. Previous studies demonstrated the effectiveness of Elevai’s proprietary exosome technology in hair restoration, showing promising results in reversing hair thinning, reducing the signs of scalp inflammation, and promoting the recovery of dormant or miniaturized hair follicles.
Positioned for Market Leadership
“This launch marks a pivotal milestone for Elevai Skincare as its first new product launch since its current two and only products were launched in 2022, reflecting the strategic push for additional revenue streams under Elevai Labs’ new leadership,” said Graydon Bensler, Chief Executive Officer of Elevai Skincare parent company, Elevai Labs. “The Root Renewal System adds a breakthrough product to Elevai Skincare’s portfolio, addressing growing demand in the high-growth hair care market. The Skincare sales team will be leveraging their strong relationships in the medical aesthetics space to position this product for early success, with a broader consumer rollout planned for January 2025. This launch not only strengthens Elevai Skincare’s product offering but also creates significant new opportunities for growth and profitability.”
About Elevai Labs, Inc.
Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit www.elevailabs.com.
About Elevai Skincare Inc.
A subsidiary of Elevai, Elevai Skincare is a medical aesthetics company developing and commercializing cutting-edge physician-dispensed skin and hair care applications that focuses on science-backed applications for the physician-dispensed market, utilizing cutting-edge technologies to redefine skincare and hair care, including its stem cell exosome technology. For more information, please visit elevaiskincare.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: Elevai’s limited operating history and historical losses; Elevai’s ability to raise additional funding to complete the development and any commercialization of its product candidates; Elevai’s dependence on the success of its product candidates EL-22 and EL-32; that Elevai may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Elevai’s ability to obtain, maintain and protect its intellectual property; Elevai’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and Elevai’s expectations regarding its growth, strategy, progress and the design, objectives and timing of its studies. These and other risks are described more fully in Elevai’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
IR@ElevaiLabs.com
1 “One of the Biggest Innovations in Hair Loss We’ve Seen in Twenty-Five Years” — BosleyMD® Teams With Start-up Yuva Biosciences in National Launch of Breakthrough Technology | Business Wire
FAQ
What is Elevai Labs' (ELAB) new Root Renewal System?
When will Elevai Labs' (ELAB) Root Renewal System be available for e-commerce?
What technologies are used in Elevai Labs' (ELAB) Root Renewal System?
